Is Ozempic Linked to Gastroparesis? A Massachusetts Patient's Checklist

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Specific Legal Risk

If you're taking Ozempic and experiencing persistent nausea, bloating, or vomiting, you may be dealing with gastroparesis—a condition where the stomach empties too slowly. Decades of pharmacovigilance have established that certain medications can disrupt gastric motility, and recent reports highlight GLP-1 agonists like Ozempic. This page provides a checklist of symptoms and monitoring steps for Massachusetts patients.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which is a known mechanism that can contribute to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has emerged as a significant concern for patients and clinicians. Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, postprandial fullness, and abdominal pain. These symptoms overlap with common gastrointestinal adverse reactions reported in Ozempic clinical trials. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients with type 2 diabetes mellitus include nausea (placebo 6.1%, Ozempic 0.5 mg 15.8%, Ozempic 1 mg 20.3%), vomiting (placebo 2.3%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 9.2%), diarrhea (placebo 1.9%, Ozempic 0.5 mg 8.5%, Ozempic 1 mg 8.8%), abdominal pain (placebo 4.6%, Ozempic 0.5 mg 7.3%, Ozempic 1 mg 5.7%), and constipation (placebo 1.5%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms are consistent with gastroparesis, though the label does not explicitly list gastroparesis as a separate adverse reaction.

Mechanism and Risk of Gastroparesis with Ozempic

Mechanistically, GLP-1 receptor agonists like Ozempic delay gastric emptying by inhibiting gastric motility and increasing pyloric tone. This pharmacodynamic effect is intended to improve glycemic control but can lead to prolonged gastric retention. In severe cases, this may progress to gastroparesis, with symptoms persisting even after drug discontinuation. The label acknowledges that there have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for significant gastric retention associated with these medications. The adequacy of warnings regarding Ozempic and gastroparesis is a key risk consideration. The label does not specifically warn about gastroparesis as a distinct adverse effect, instead grouping symptoms under gastrointestinal adverse reactions. Patients may not be adequately informed about the risk of developing a chronic condition like gastroparesis, which can lead to malnutrition, weight loss, and reduced quality of life. The label does advise caution in patients with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not address gastroparesis specifically.

Legal Considerations and Statute of Limitations in Massachusetts

For affected patients in Massachusetts, attorney-related considerations include the statute of limitations for filing a product liability claim. In Massachusetts, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For claims involving Ozempic and gastroparesis, the timeline between exposure and documented harm is critical. Symptoms may develop during dose escalation or after prolonged use, and the diagnosis of gastroparesis may be delayed due to symptom overlap with other gastrointestinal conditions. Patients should document the start date of Ozempic use, onset of symptoms, and date of formal diagnosis to establish the timeline. Legal claims may focus on failure to warn, as the label does not explicitly mention gastroparesis. Evidence from clinical trials shows a clear dose-response relationship for gastrointestinal adverse reactions, with higher doses associated with increased rates of nausea, vomiting, and diarrhea (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This supports the argument that the manufacturer should have provided more specific warnings about the risk of gastroparesis. Patients should consult with an attorney experienced in pharmaceutical litigation to evaluate their case within the applicable statute of limitations.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Massachusetts?

In Massachusetts, the statute of limitations for personal injury claims, including product liability claims related to Ozempic and gastroparesis, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. It is crucial to consult with an attorney promptly to ensure your claim is filed within this time frame.

Does the Ozempic label warn about gastroparesis?

The Ozempic label does not explicitly list gastroparesis as a separate adverse reaction. Instead, it groups symptoms such as nausea, vomiting, and abdominal pain under gastrointestinal adverse reactions. This lack of specific warning may be a basis for legal claims focusing on failure to warn.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.